
VEXAS syndrome is a newly described adult-onset autoinflammatory disorder, predominantly affecting males (median age, 68), and recognized by somatic mutations in the UBA1 gene in blood-forming cells of the X chromosome. This rare disease causes systemic inflammation and abnormalities in the blood, with high morbidity and mortality when untreated.
VEXAS syndrome has been defined by mutations in the UBA1 gene and represents a rare but life-threatening condition affecting mainly men over the age of 50. Thus, early diagnosis of VEXAS is critical, since there is no prevention, and it probably has an overlap with other inflammatory conditions concerning signs and symptoms. Making the diagnosis early on may ease symptoms and ultimately prolong survival with timely diagnosis, appropriate treatment with steroids or immunosuppressants, or definitive therapy with a continued option of allogeneic bone marrow transplant. This is the most exciting area of research with new therapies, so education about this condition and timely interventions for at-risk patients is paramount.
Disclaimer- This information is for educational purposes only and is not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment of any medical condition.
BRIEF-Hims & Hers Health Enters Australia, Marks First Asia-Pacific Market Presence
Aug 31 (Reuters) - Hims & Hers Health, Inc.: * HIMS & HERS HEALTH, -…
Singer D4vd, charged with murdering and dismembering teen, dismisses lawyer
By Joseph Ax Aug 31 (Reuters) - The musician D4vd, facing trial on charges that…
FTC to file lawsuit alleging Amazon deceived advertisers, WSJ reports
Aug 31 (Reuters) - The U.S. Federal Trade Commission plans to file a lawsuit against…